CARD9 Deficiency Deepens Liver Injury in MASLD Mice
Metabolic dysfunction–associated steatotic liver disease MASLD has long been framed through the lens of fat, glucose, and insulin resistance. This study shifts attention to a different biological axis: fungal sensing in the gut and the adaptor protein CARD9. In a murine model fed a high-fat, high-glucose/-fructose diet, loss of CARD9 intensified liver injury, fibrosis, and signals of microbial translocation. The pattern was not subtle. Histologic damage, serum alanine aminotransferase, hepatic triglyceride content, inflammatory gene expression, and fibrotic markers all worsened in the CARD9-deficient animals.
One sentence captures the central problem: the intestine failed to contain the microbiologic burden, and the liver paid the price.
Fungal Dysbiosis Tracks With Advanced Fibrosis
Human observations set the stage for the experimental work. Patients with advanced liver fibrosis showed distinct mycobiota profiles, supporting the idea that fungal imbalance is not a bystander phenomenon in progressive MASLD. That clinical signal matters because most gut-liver discussions in metabolic liver disease have focused on bacteria, lipopolysaccharide, and barrier leakage. Here, the fungal compartment emerged as an additional source of immune stress. The investigators linked those human microbiome differences to the murine phenotype, where CARD9 deficiency and dietary stress converged on a more aggressive liver-injury program.
The biologic logic is compelling. CARD9 is a core adaptor in antifungal innate immunity, so impaired CARD9 signaling can blunt host recognition of fungal organisms and alter downstream mucosal defense. In the setting of metabolic stress, that defect appears to amplify dysbiosis rather than contain it. The consequence is a gut environment less able to restrain translocation of microbial products into the portal circulation, with direct implications for hepatic inflammation and fibrogenesis.
Barrier Failure, Not Just Steatosis, Drove the Injury Signal
The liver phenotype in the CARD9-deficient mice extended beyond fat accumulation. Serum ALT rose, hepatic triglyceride content increased, serum lipopolysaccharide was elevated, and Sirius red staining showed more fibrosis in the deficient animals exposed to the high-fat, high-glucose/-fructose diet. Expression of fibrotic and inflammatory genes also climbed, including Col1a1, Col3a1, Col4a1, and Tnf. Those molecular readouts align with the histology: a more inflamed, more fibrogenic liver in which barrier dysfunction is feeding the disease process.
The intestinal compartment helps explain why. CARD9 was detected in intestinal enterocytes, not only in myeloid cells, expanding the protein’s relevance beyond conventional antifungal immunity. Under metabolic stress, intestinal CARD9 expression fell. In organoid experiments, CARD9 inhibition reduced expression of Reg3g, the tight junction protein ZO-1, and the antifungal enteroendocrine hormone PYY. Each of those changes points in the same direction: weakened antimicrobial defense, loosened epithelial integrity, and reduced local antifungal restraint.
Enterocytes Join Myeloid Cells in the Fungal Defense Network
The enterocyte finding is one of the most clinically interesting parts of the work because it broadens the cell types that may govern the gut-liver axis in MASLD. CARD9 has been treated largely as a myeloid signaling molecule, but the detection of CARD9 in intestinal epithelial cells suggests a more distributed defense system. When that epithelial program is suppressed by metabolic stress, the barrier becomes more permissive. Fungal products and other microbial signals can then move across the mucosa and into the portal vein, where they trigger Kupffer cell activation, inflammatory cascades, and fibrotic remodeling.
PYY deserves special attention in that context. Its reduction in CARD9-inhibited organoids suggests that antifungal surveillance and enteroendocrine signaling are linked more tightly than previously appreciated. The work does not claim that PYY alone explains the phenotype, but its suppression fits a broader failure of mucosal homeostasis. ZO-1 loss adds structural relevance, since tight-junction disruption is a direct route to increased permeability. Reg3g loss adds antimicrobial weakness at the mucosal surface. Together, those shifts create a plausible route from fungal dysbiosis to hepatic injury.
Why the Fibrosis Signal Matters Clinically
Fibrosis remains the feature that separates benign steatosis from progressive liver disease. In this model, CARD9 deficiency did not merely worsen lipid accumulation; it pushed the system toward more injury, more inflammation, and more collagen deposition. That distinction is important because it suggests a mechanism that could influence disease trajectory rather than only hepatic fat content. If the gut barrier is part of the fibrotic driver, then targeting fungal sensing or epithelial defense could eventually complement metabolic therapy.
For now, the study stays within preclinical boundaries, but the implications are concrete. MASLD is heterogeneous, and patients with advanced fibrosis may represent a subgroup in which fungal dysbiosis and impaired CARD9 signaling contribute to worse outcomes. The data support a model in which fungal sensing is not peripheral to metabolic liver disease but embedded in the pathogenesis of progression itself.
What the Data Support and What They Do Not
This is a murine study with human microbiota observations, not a treatment trial. It does not establish whether restoring CARD9 activity, correcting fungal dysbiosis, or strengthening the intestinal barrier will reverse fibrosis in patients. It also does not define whether fungal signatures are a cause, a consequence, or both in advanced human MASLD. Even so, the combined human and animal findings make a strong case that the gut mycobiome deserves a seat at the table in liver-disease research.
The most immediate clinical consequence is conceptual rather than therapeutic: MASLD should no longer be viewed only through metabolic and bacterial mechanisms. Fungal sensing, epithelial defense, and barrier integrity now appear to be part of the same disease circuit, and CARD9 sits at its center.